- Home
- BVFL vs NTHI Comparison
BVFL vs NTHI Comparison
Compare BVFL & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BVFL | NTHI |
|---|---|---|
| Founded | 1873 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.2M | 195.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BVFL | NTHI |
|---|---|---|
| Price | $19.41 | $7.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 21.8K | ★ 68.4K |
| Earning Date | 01-26-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $38,669,000.00 | $59,990.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.72 | ★ N/A |
| Revenue Growth | ★ 1.69 | N/A |
| 52 Week Low | $13.53 | $3.20 |
| 52 Week High | $19.74 | $25.00 |
Technical Indicators
Market Signals| Indicator | BVFL | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 62.22 | 37.62 |
| Support Level | $18.93 | $8.63 |
| Resistance Level | $19.74 | $10.44 |
| Average True Range (ATR) | 0.54 | 0.89 |
| MACD | 0.05 | -0.10 |
| Stochastic Oscillator | 74.16 | 7.32 |
Price Performance
Historical ComparisonAbout BVFL BV Financial Inc.
BV Financial Inc is a federally-chartered savings and loan holding company engaged in offering traditional financial services to consumers and businesses. The company offers savings, interest checking, money market, personal and business checking, non-interest checking, education savings, small business checking, and business checking and certificates of deposit and IRA certificates of deposit. The Company's sources of revenue are derived from interest and dividends earned on loans and investment securities.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).